Monitoring minimal residual disease using chromosomal translocations in childhood ALL

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 1, 2002, Pages 21-35

  Cazzaniga, Giovanni ^a   Rossi, Vincenzo ^a   Biondi, Andrea ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Childhood ALL; Chromosomal translocations; Minimal residual disease

Indexed keywords

HYBRID PROTEIN; DNA; BCR ABL PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; MYC PROTEIN; PROTEIN; PROTEIN SIL; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER RECURRENCE; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CLONE; CONTROLLED STUDY; GENE DISRUPTION; GENETIC HETEROGENEITY; HUMAN; LEUKEMIA REMISSION; LEUKEMOGENESIS; MEDICAL DECISION MAKING; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; ACUTE LYMPHOCYTIC LEUKEMIA; GENE TRANSLOCATION; GENETICS; METHODOLOGY; REVIEW; STANDARD; CHROMOSOME 1P; CHROMOSOME 21Q; CHROMOSOME DELETION; DECISION MAKING; FUSION GENE; GENE ACTIVATION; LEUKEMIA RELAPSE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CHILD; DNA, NEOPLASM; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC;

EID: 0036009605     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2002.0183     Document Type: Article

References (90)

1. Childhood leukaemias
2. Detection of minimal residual disease in acute myeloid leukaemia: Methodologies, clinical and biological significance
3. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase
4. Polymerase chain reaction: The molecular microscope of residual disease
5. Oncogenic transcription factors in the human acute leukaemias
6. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia
7. Cross-lineage T-cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B-acute lymphoblastic leukaemias: Alternative PCR targets for detection of minimal residual disease
8. Detection of minimal residual disease in acute leukaemia patients
9. Chromosomal translocations in human cancer
10. The molecular basis of leukaemia
11. Detection of minimal residual disease in acute leukaemia: Methodological and clinical significance
12. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis
13. Standardised RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukaemia for detection of minimal residual disease. Report of the BIOMED-I Concerted Action: Investigation of minimal disease in acute leukaemia
14. Detection of minimal residual disease in patients with AMLI/ETO-associated acute myeloid leukaemia using a novel quantitative reverse transcription polymerase chain reaction assay
15. Quantitative PCR techniques and applications
16. Real time quantitative PCR
17. Detection and quantification of residual disease in chronic myelogenous leukaemia
18. Rapid and sensitive minimal residual disease detection in acute leukaemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AMLI fusion transcript
19. Real-time RT-PCR for the detection and quantification of AMLI/MTG8 fusion transcripts in t(8;21)-positive AML patients
20. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukaemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology
21. Product differentiation by analysis of DNA melting curves during the polymerase chain reaction
22. Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukaemia
23. Light Cycler Technology for the quantification of bcr/abl fusion transcripts
24. Rapid geno-typing and quantification on the LightCycler with hybridisation probes
25. Current recommendations for positive controls in RT-PCR assays
26. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease
27. Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation
28. Investigation of minimal residual disease in acute non-lymphoblastic leukaemia: International standardisation and clinical evaluation
29. BIOMED-I concerted action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukaemia (T-ALL)
30. Primers and protocols for standardised detection of minimal residual disease in acute lymphoblastic leukaemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: Report of BIOMED-ICONCERTED ACTION: Investigation of minimal residual disease in acute leukaemia
31. European standardisation and quality control programs of real-time RT-PCR for minimal residual disease detection of fusion gene transcripts in multicentric therapeutic trials for leukaemia patients
32. Biological and therapeutic aspects of infant leukemia
33. ALL1 gene alterations in acute leukemia: Biological and clinical aspects
34. Detection of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukaemias with the t(4;11) translocation
35. Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-1/AF-4 positive-acute lymphoblastic leukaemia
36. Detection of chimeric mRNAs by reverse transcriptase-polymerase chain reaction for diagnosis and monitoring of acute leukaemias with 11q23 abnormalities
37. A prospective study of residual-disease monitoring of the ALLI/AF4 transcript in patients with t(4;11) acute lymphoblastic leukaemia
38. Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19)
39. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: Clinical features and molecular pathogenesis
40. Molecular variants of the 1;19 chromosomal translocation in pediatric acute lymphoblastic leukemia (ALL)
41. Reverse transcriptase/polymerase chain reaction follow-up and minimal residual disease detection in t(1;19)-positive acute lymphoblastic leukaemia
42. Persistence of E2A/PBXI transcript in t(1;19) childhood acute lymphoblastic leukaemia, correlation with chemotherapy intensity and clinical outcome
43. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 ALL-BFM 90 and CoALL-05-92
44. MRC Adult Leukaemia Working Party. Cytogenetics adds independent prognostic information in adult acute lymphoblastic leukaemia on MRC trial UKALL XA
45. Consistent involvement of the bcr gene by 9;22 breakpoints in pediatric acute leukemias
46. The molecular biology of chronic myeloid leukemia
47. Philadelphia chromosome-positive acute lymphocytic leukemia
48. Detection of chimeric BCR/ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction
49. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
50. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome
51. Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: Possible eradication of minimal residual disease by marrow transplantation
52. Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: Comparison of blood and bone marrow
53. PCR-monitoring of minimal residual leukaemia after conventional chemotherapy and bone marrow transplantation in BCR-ABL-positive acute lymphoblastic leukaemia
54. Good correlation between RT-PCR analysis and relapse in Philadelphia (Phl)-positive acute lymphoblastic leukemia (ALL)
55. Effect of the Philadelphia chromosome on minimal residual disease in acute lymphoblastic leukemia
56. Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction
57. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia
58. Immune response to Philadelphia chromosome-positive acute lymphoblastic leukemia induced by expression of CD80, interleukin 2, and granulocyte-macrophage colony-stimulating factor
59. Real-time quantitation of bcr-abl transcripts in haematological malignancies
60. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
61. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia
62. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion
63. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicentre therapy trials
64. Prospective evaluation of t(12;21) prognostic impact in childhood ALL. Results of the Italian ALL-AIEOP 95 therapy protocol
65. TEL/AML1 fusion gene is a rare event in adult acute lymphoblastic leukemia
66. M.R.C. Adult Leukaemia Working Party. TEL-AML1 fusion in acute lymphoblastic leukaemia of adults
67. Minimal residual disease with TEL-AML1 fusion transcript in childhood acute lymphoblastic leukaemia with t(12;21)
68. Analysis of ETV6/AML1 abnormalities in acute lymphoblastic leukaemia: Incidence, alternative spliced forms and minimal residual disease value
69. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with excellent prognosis
70. TEL/AML-1 dimerises and is associated with a favorable outcome in childhood acute lymphoblastic leukemia
71. Incidence of TEL-AML1 fusion in children with relapsed acute lymphoblastic leukemia
72. Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favourable prognosis for this genetic subgroup
73. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse
74. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia
75. Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia
76. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia
77. Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia
78. Minimal residual disease with TEL/AML1 fusion transcript in childhood acute lymphoblastic leukaemia with t(12;21)
79. TEL/AML1 positivity in childhood ALL: Average or better prognosis
80. Frequency and DNA sequence of tal-I rearrangement in children with T-cell acute lymphoblastic leukaemia
81. Site-specific deletions involving the tal-I and sil genes are restricted to cells of the T cell receptor alpha/beta lineage, T cell receptor delta gene deletion mechanism affects multiple genes
82. Site-specific recombination of the tal-I gene is a common occurrence in human T cell leukaemia
83. Rearrangements of the tal-I locus as clonal markers for T cell acute lymphoblastic leukemia
84. Clinical significance of TALI gene alteration in childhood T-cell acute lymphoblastic leukemia and lymphoma
85. Simultaneous SIL-TALI RT-PCR detection of all tal(d) deletions and identification of novel tal(d) variants
86. RT/PCR detection of SIL-TAL-I fusion mRNA in Chinese T-cell acute lymphoblastic leukemia (T-ALL)
87. Quantification of minimal residual disease in T-lineage acute lymphoblastic leukemia with the TAL-1 deletion using a standardized real-time PCR assay
88. SIL-TALI deletion in T-cell acute lymphoblastic leukemia
89. Application of long PCR to detect t(8;14)(q24;q32) translocations in childhood Burkitt's lymphoma and B-ALL
90. Improved long-distance polymerase chain reaction for the detection of t(8;14)(q24;q32) in Burkitt's lymphomas